Northwest Biotherapeutics (NWBO) : During the past 4 weeks, traders have been relatively bearish on Northwest Biotherapeutics (NWBO), hence the stock is down -21.81% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -12.27% relative to the S&P 500. The 4-week change in the price of the stock is -21% and the stock has fallen -12.22% in the past 1 week.
The stock has recorded a 20-day Moving Average of 14.2% and the 50-Day Moving Average is 28.51%. Northwest Biotherapeutics (NASDAQ:NWBO): On Fridays trading session , Opening price of the stock was $0.429 with an intraday high of $0.429. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.3871. However, the stock managed to close at $0.395, a loss of 4.36% for the day. On the previous day, the stock had closed at $0.413. The total traded volume of the day was 656,235 shares.
The company Insiders own 45.67% of Northwest Biotherapeutics shares according to the proxy statements. Institutional Investors own 36.97% of Northwest Biotherapeutics shares.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Companys platform technology, DCVax, uses activated dendritic cells to mobilize a patients own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patients tumor. DCVax product lines are made from the patients own dendritic cells, which are freshly isolated, and matured and activated. The Companys DCVax product lines include DCVax-L, DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen, PSMA (Prostate Specific Membrane Antigen), which is found on all late stage prostate cancers.